RNS Number : 9610A
IXICO plc
25 January 2024
 

 

25 January 2024

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

 

 

RESOLUTION

VOTES
FOR

%

VOTES
AGAINST

%

VOTES
TOTAL

% ISC VOTED

VOTES
WITHHELD

1

Reports and Accounts

 

20,820,635

99.92%

16,913

0.08%

20,837,548

43.10

7,409

2a

Re-election of Mark Warne

 

20,811,026

99.87%

26,948

0.13%

20,837,974

43.10

6,983

2b

Election of Dipti Amin

20,814,152

99.92%

17,113

0.08%

20,831,265

43.08

13,692

3

Appointment of Moore Kingston Smith Auditors

20,819,713

99.88%

24,122

0.12%

20,843,835

43.11

1,122

4

Allotment of Securities

 

20,819,913

99.89%

23,822

0.11%

20,843,735

43.11

1,222

5

* Disapply Pre-Emption Provisions

20,800,863

99.80%

42,572

0.20%

20,843,435

43.11

1,522

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.    

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7499

 

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 



 

 

Cavendish Capital Markets Limited (Nominated Adviser and

Sole Broker)

+44 (0) 20 7220 0500

 

Giles Balleny / Dan Hodkinson (Corporate Finance)

Michael F Johnson / Tamar Cranford Smith (Sales)




 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGQKPBPPBKDKDB